Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481643 | 1.00 | MIF (0.53) | MIFSMN1; SMN2GPR183EIF2AK2CSNK2A2 | |
| SCHEMBL1469976 | 0.86 | MIF (0.67) | MIFSMN1; SMN2GPR183EIF2AK2CSNK2A2 | |
| SCHEMBL1469977 | 0.86 | MIF (0.67) | MIFSMN1; SMN2GPR183EIF2AK2CSNK2A2 | |
| Hydrochloric Acid SCHEMBL6818301 | 0.84 | MIF (0.65) | MIFSMN1; SMN2GPR183EIF2AK2CSNK2A2 | |
| SCHEMBL17157713 | 0.84 | SMN1; SMN2 (0.54) | MIFSMN1; SMN2GPR183LMNAMEN1 | |
| SCHEMBL17157715 | 0.84 | SMN1; SMN2 (0.54) | MIFSMN1; SMN2GPR183LMNAMEN1 | |
| SCHEMBL65191 | 0.83 | TDO2 (0.58) | MIFEIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL29535211 | 0.83 | TDO2 (0.58) | MIFEIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL65190 | 0.83 | TDO2 (0.58) | MIFEIF2AK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL14086377 | 0.83 | TDO2 (0.58) | MIFEIF2AK2CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747059-A1 | PERVAPORATION COMPOSITE MEMBRANES | McMaster University (CA) | 2007-01-31 | — | — | EP | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| CN-114230519-B | Pleuromutilin cinnamate compounds with drug-resistant bacteria resisting activity, and synthetic method and application thereof | 西咸新区沣厚原创医药科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-110914242-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-114230519-A | Pleuromutilin cinnamate compounds with drug-resistant bacterium resisting activity and synthesis method and application thereof | 陕西科技大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-111233927-B | Thiamine compound, preparation method and pharmaceutical composition thereof | 上海日馨生物科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-111233927-A | Thiamine compound, preparation method and pharmaceutical composition thereof | 上海日馨生物科技有限公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-110914242-A | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-2226192-B1 | DRYING SUBSTANCES, PREPARATION AND USE THEREOF | ORIDION MEDICAL 1987 LTD (IL) | 2016-08-31 | — | — | EP | disclosed |
| US-9376420-B2 | 4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-06-28 | — | — | US | disclosed |
| US-20040033434-A1 | Sulfonium salt compound | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1314725-A1 | SULFONIUM SALT COMPOUND | Wako Pure Chemical Industries, Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-6562844-B2 | Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-6531470-B1 | Antimicrobial compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-11 | — | — | US | disclosed |
| US-6239152-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1049682-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | Versicor, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999037630-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | VERSICOR, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033434-A1 | Sulfonium salt compound | SPIN1, RER1, SPIN2B | MIF 3614/4885SMN1; SMN2 838/4885GPR183 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.